Related Experiment Video
Updated: Jul 12, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
17.7K
Treatment optimization in early triple negative breast cancer
Elias Kotteas1, Luca Boscolo Bielo2,3, Carmine Valenza2,3
1Oncology Unit, 3rd Department of Internal Medicine, National & Kapodistrian University of Athens, Athens, Greece.
Expert Review of Anticancer Therapy
|October 24, 2023
Summary
Optimizing early-stage triple-negative breast cancer (TNBC) treatment involves risk-adapted strategies. Achieving pathological complete response (pCR) improves prognosis, guiding personalized therapeutic de-intensification for better outcomes.
Area of Science:
- Oncology
- Breast Cancer Research
- Clinical Therapeutics
Background:
- Early-stage triple-negative breast cancer (TNBC) treatment has evolved significantly.
- Pathological complete response (pCR) to neoadjuvant therapy is a key prognostic indicator.
- A consolidated treatment algorithm balancing efficacy and toxicity is lacking.
Purpose of the Study:
- To review current treatments for early TNBC.
- To frame a therapeutic approach for risk-adapted treatment optimization.
- To identify areas for clinical implementation in early TNBC management.
Main Methods:
- Review of clinical trials and evidence in early TNBC.
- Analysis of current clinical practice and therapeutic strategies.
- Identification of novel biomarkers and prognostic indicators.
Main Results:
- Neoadjuvant treatment response, particularly pCR, offers prognostic value.
- Treatment de-intensification is possible for select early TNBC cases (e.g., small tumors).
- Biomarker-informed and response-guided strategies are emerging.
Conclusions:
- Treatment optimization for early TNBC should focus on patient-centric outcomes, reduced toxicity, and improved quality of life.
- Risk-adapted modulation, incorporating baseline risk, cancer biology, and post-surgery biomarkers, is crucial.
- Innovative approaches are needed to refine personalized treatment strategies for early TNBC.
Related Concept Videos
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K